High-dose aminothiadiazole in advanced colorectal cancer - An Illinois Cancer Center phase II trial

Gershon Y. Locker*, Lary Kilton, Janardan D. Khandekar, Thomas E. Lad, Richard H. Knop, Kathy Albain, Richard Blough, Suzanne French, Al B. Benson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Thirty-three patients with advanced colorectal carcinoma were entered on a phase II trial of weekly IV aminothiadiazole (175 mg/m2 escalated to 200 mg/m2) with concomitant allopurinol and non-steroidal anti-inflammatory agents (NSAID's). Toxicity was predominantly GI, cutaneous, and chest pain/dyspnea. Twenty-five percent of patients had grade 3 or 4 toxicity. There were no responses in 27 evaluable patients. Median survival was 12 months. Aminothiadiazole, at higher doses than used in previous reports, when given with NSAID's, had no significant activity against large bowel cancer.

Original languageEnglish (US)
Pages (from-to)299-301
Number of pages3
JournalInvestigational New Drugs
Volume12
Issue number4
DOIs
StatePublished - Dec 1994

Keywords

  • ATDA
  • aminothiadiazole
  • colorectal cancer
  • large bowel carcinoma
  • phase II trial

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'High-dose aminothiadiazole in advanced colorectal cancer - An Illinois Cancer Center phase II trial'. Together they form a unique fingerprint.

Cite this